Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70678 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Anders Strathe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptides, Models, Biological, Pediatric Obesity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Novo Nordisk A/S, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Abstract (Originalsprache)
Aims
Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model‐informed drug development (MIDD) to evaluate whether a 1.7‐mg maintenance dose provides comparable exposure, tolerability and BMI effects in adolescents versus adults and versus the 2.4‐mg dose. Materials and Methods Simulation analyses combined pharmacokinetic, BMI and safety data from the adolescent STEP TEENS Phase 3 study ( N = 201) and the adult semaglutide STEP studies (Phases 2–3; ~3100 participants). Data across doses (0.25–2.4 mg) were used to model concentration–time profiles, extrapolate percent change in BMI for 1.7 mg, estimate proportions achieving ≥ 5%, ≥ 10% and ≥ 15% BMI reductions and predict gastrointestinal adverse event (AE) incidence as a function of exposure.
Results
Modelled semaglutide concentrations over 68 weeks were similar between adolescents and adults; body weight was the main covariate influencing exposure. For adolescents, the 1.7‐mg dose showed comparable efficacy to 2.4 mg (mean BMI change: −15.2% vs. −17.4%) and was significantly greater than placebo ( p < 0.01). Predicted proportions achieving prespecified BMI reduction thresholds and gastrointestinal AE profiles were similar across populations and doses.
Conclusions
PK/PD and safety modelling indicated 1.7 mg semaglutide provides comparable exposure, tolerability and meaningful BMI reduction in adolescents versus adults and versus 2.4 mg. These results supported approval of 1.7 mg for adolescents ≥ 12 years in the November 2024 Wegovy label, obviating a dedicated adolescent 1.7‐mg placebo trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk A/S, Søborg, Denmark.
- Center for Pediatric Obesity Medicine and Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Paracelsus Medical University, Department of Pediatrics, Salzburg, Austria.
ORCID-Profile: Anders Strathe, Eric M Bomberg, Rune Viig Overgaard
Förderung
- NIDDK NIH HHS
- Novo Nordisk A/S
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Zitieren
APA
Strathe, A., Bomberg, E. M., Jensch, G., Kildegaard, J., Harder-Lauridsen, N. M., Weghuber, D., & Overgaard, R. V. (2026). Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70678
Vancouver
Strathe A, Bomberg EM, Jensch G, Kildegaard J, Harder-Lauridsen NM, Weghuber D, et al. Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70678
BibTeX
@article{Strathe2026,
author = {Strathe, Anders and Bomberg, Eric M and Jensch, Garrit and Kildegaard, Jonas and Harder-Lauridsen, Nina M and Weghuber, Daniel and Overgaard, Rune Viig},
title = {Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70678}
}
EUVIMED